BRIACELL THERAPEUTICS CORP. Impairment of Intangible Assets, Finite-lived
BRIACELL THERAPEUTICS CORP. (BCTX) reported Impairment of Intangible Assets, Finite-lived of $0 for the 12-month period ending 2022-07-31, per its 10-K filed 2022-10-28.
Discontinued › Expense Statement › Operating Expenses
us-gaap:ImpairmentOfIntangibleAssetsFinitelived · last filed 2022-10-28
- BRIACELL THERAPEUTICS CORP. impairment of intangible assets, finite-lived for fiscal 2022 was $0.00.
- BRIACELL THERAPEUTICS CORP. impairment of intangible assets, finite-lived for fiscal 2021 was $0.00.
| Period end | Impairment of Intangible Assets, Finite-lived 12 month |
|---|---|
| 2022-07-31 | $0.00 10-K · filed 2022-10-28 |
| 2021-07-31 | $0.00 10-K · filed 2022-10-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| PMGC Holdings Inc. (ELAB) | United States | $0.037B | |
| Seres Therapeutics, Inc. (MCRB) | United States | $0.036B | -3.45 |
| FILANA THERAPEUTICS, INC. (FLNA) | United States | $0.038B | -1.05 |
| Actinium Pharmaceuticals, Inc. (ATNM) | United States | $0.038B | 2.73 |
| MIRA PHARMACEUTICALS, INC. (MIRA) | United States | $0.036B | -4.30 |
| Celularity Inc (CELU) | United States | $0.038B | -0.34 |
| CervoMed Inc. (CRVO) | United States | $0.038B | -1.39 |
| Edesa Biotech, Inc. (EDSA) | Canada | $0.039B | |
| ROCKWELL MEDICAL, INC. (RMTI) | United States | $0.035B | |
| Karyopharm Therapeutics Inc. (KPTI) | United States | $0.039B | -0.98 |